Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the
hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential …

1Centre for Medical Education, Queen's University, Belfast, 2MRC Molecular Haematology
Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine …

The clinical course of polycythemia vera (PV) is marked by a high incidence of thrombotic
complications; fibrotic and leukemic disease transformations are additional causes of …

Purpose The incidence of hematologic malignancies during pregnancy is 0.02%. However,
this figure is increasing, as women delay conception until a later age. Systemic symptoms …

Pregnancy in the context of myeloproliferative neoplasms (MPN) poses unique fetal and
maternal challenges. Current literature in this regard mostly involves essential …

The reported higher risk of maternal and fetal complications in women with
myeloproliferative neoplasms (MPN) poses challenge during pregnancy. A national …

The combined incidence of classical Philadelphia‐negative myeloproliferative neoplasm
(MPN) is 6–9/100 000 with a peak frequency between 50 and 70 years. MPN is less frequent …

Myeloproliferative neoplasms (MPN) are associated with inferior pregnancy outcome,
however, little is known about fertility and childbearing potential in women with MPN. In this …